Global Transdermal Patch Market Set to Surge, Driven by Innovation in Pain Management

The global transdermal patch market, currently valued at $7.8 billion, is expected to expand to nearly $10.95 billion by 2030. This growth is largely fueled by the increasing demand for pain patches, which offer a safer alternative to traditional opioid use and address the needs of aging populations suffering from chronic pain. Nutriband Inc. (NASDAQ: NTRB) is making strides with its AVERSA Fentanyl patch, a product designed to reduce abuse, misuse, and accidental exposure, with potential peak annual US sales estimated between 80 million and 200 million dollars.

Other companies are also contributing to this sector's growth. Collegium Pharmaceutical, Inc. (Nasdaq: COLL) has reported consistent revenue growth, thanks to its ADHD medication Jornay PM and chronic pain medications such as Belbuca, Xtampza ER, and the Nucynta franchise. Assertio Holdings, Inc. (Nasdaq: ASRT) is focusing on optimizing its operations and prioritizing high-potential assets, with Rolvedon and Sympazan exceeding performance expectations. Meanwhile, Aquestive Therapeutics, Inc. (Nasdaq: AQST) is pioneering innovative drug delivery technologies, including the Anaphylm™ oral sublingual film for severe allergic reactions, which is close to receiving FDA approval.

These developments highlight the pharmaceutical industry's shift towards more innovative and patient-friendly drug delivery methods. The advancements in transdermal patch technology not only promise enhanced efficacy and safety in pain management but also represent a significant step forward in addressing the global opioid crisis and improving the quality of life for patients with chronic conditions. For more information on the AVERSA Fentanyl patch, visit https://www.nutriband.com.